<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532712</url>
  </required_header>
  <id_info>
    <org_study_id>EC-18-101</org_study_id>
    <nct_id>NCT02532712</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, Phase I Clinical Trial to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enzychem Lifesciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enzychem Lifesciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Dose block-randomized, Double-blind, Placebo-controlled, Single and Multiple
      Ascending Dose Escalation, Phase I clinical trial to assess the safety, tolerability and
      pharmacokinetics of single-dose and multiple-dose oral administration of the investigational
      product, EC-18 (study drug) in healthy adult male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In vitro and in vivo efficacy studies and clinical trials have shown that EC-18 has a mode of
      action of improving neutropenia by promoting neutrophil production from hematopoietic stem
      cells and at the same time, efficiently controlling STAT6/Complement 3(C3), suggesting its
      potential to be developed as an orally administered new drug for treatment of neutropenia
      resulting from decreased neutrophils caused by administration of an anticancer agent.

      This study is a Dose block-randomized, Double-blind, Placebo-controlled, Single and Multiple
      Ascending Dose Escalation, Phase I clinical trial to assess the safety, tolerability and
      pharmacokinetics of single-dose and multiple-dose oral administration of the investigational
      product, EC-18 (study drug) in healthy adult male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No. and severity of Adverse event as a Measure of Safety and Tolerability</measure>
    <time_frame>From date of D-1 until Follow-up visit: up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs, physical examination, clinical laboratory tests, ECG as a Measure of Safety and Tolerability</measure>
    <time_frame>From date of screening until Follow-up visit: up to 60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following single oral dose: Cmax (Maximum observed plasma drug concentration)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following single oral dose: Tmax (Time of maximum drug concentration)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following single oral dose: AUClast (Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following single oral dose: AUCinf (Area under the plasma concentration-time curve from time zero extrapolated to the infinite time)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following single oral dose: t1/2 (Half-life)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following single oral dose: CL/F (Apparent total clearance of the drug from plasma after oral administration)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: Cmax,ss (Maximum (peak) steady-state plasma drug concentration during a dosage interval)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: Cmin,ss (Minimum steady-state plasma drug concentration during a dosage interval)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: Cavg,ss (Average steady-state plasma drug concentration during multiple-dose administration)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: Fluctuation</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: t1/2 (half-life)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: AUCτ (Area under the plasma concentration-time curve from time zero to time t)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: AUCinf (Area under the plasma concentration-time curve from time zero to infinity)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: Cmax (Maximum (peak) plasma drug concentration)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: Tmax (Time to reach maximum (peak) plasma concentration following drug</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: CL/F (Apparent total clearance of the drug from plasma after oral administration)</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EC-18 following multiple oral doses: Accumulation index</measure>
    <time_frame>[0], 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 16, 24, 36, 48 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Chemotherapy-Induced Neutropenia</condition>
  <arm_group>
    <arm_group_label>Single dose group-Group 1-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, 500mg of Study drug(EC-18)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group-Group 1-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, 500mg of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group-Group 2-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, 1000mg of Study drug(EC-18)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group-Group 2-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, 1000mg of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group-Group 3-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, 2000mg of Study drug (EC-18)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group-Group 3-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, 2000mg of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group-Group 4-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, 4000mg of Study drug (EC-18)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group-Group 4-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, 4000mg of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group-Group 1-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose, Study drug(EC-18) 500mg, Once daily, for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group-Group 1-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dose, Placebo 500mg, Once daily, for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group-Group 2-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose, Study drug(EC-18) 1000mg, Once daily, for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group-Group 2-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dose, Placebo 1000mg, Once daily, for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group-Group 3-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose, Study drug(EC-18) 2000mg, Once daily, for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group-Group 3-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dose, Placebo 2000mg, Once daily, for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group-Group 4-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose, Study drug(EC-18) 4000mg, Once daily, for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group-Group 4-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dose, Placebo 4000mg, Once daily, for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC-18</intervention_name>
    <description>EC-18 Soft-capsule (500mg/1 capsule)</description>
    <arm_group_label>Single dose group-Group 1-Experimental</arm_group_label>
    <arm_group_label>Single dose group-Group 2-Experimental</arm_group_label>
    <arm_group_label>Single dose group-Group 3-Experimental</arm_group_label>
    <arm_group_label>Single dose group-Group 4-Experimental</arm_group_label>
    <arm_group_label>Multiple dose group-Group 1-Experimental</arm_group_label>
    <arm_group_label>Multiple dose group-Group 2-Experimental</arm_group_label>
    <arm_group_label>Multiple dose group-Group 3-Experimental</arm_group_label>
    <arm_group_label>Multiple dose group-Group 4-Experimental</arm_group_label>
    <other_name>EC18 Soft-capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with same shape and size</description>
    <arm_group_label>Single dose group-Group 1-Placebo</arm_group_label>
    <arm_group_label>Single dose group-Group 2-Placebo</arm_group_label>
    <arm_group_label>Single dose group-Group 3-Placebo</arm_group_label>
    <arm_group_label>Single dose group-Group 4-Placebo</arm_group_label>
    <arm_group_label>Multiple dose group-Group 1-Placebo</arm_group_label>
    <arm_group_label>Multiple dose group-Group 2-Placebo</arm_group_label>
    <arm_group_label>Multiple dose group-Group 3-Placebo</arm_group_label>
    <arm_group_label>Multiple dose group-Group 4-Placebo</arm_group_label>
    <other_name>Placebo for EC-18 (Sofe-capsule)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male aged between 19 and 45 years, inclusive, at the time of providing
             the informed consent form

          -  Body weight ≥ 50 kg, and calculated BMI in the range of 18.5 kg/m2 ≤ BMI &lt; 25.0 kg/m2
             ☞ BMI(body mass index) = Body weight (kg)/[height (m)]2

          -  No inherited or chronic disease and pathologic symptoms or findings from internal
             examinations

          -  Eligible subject based on findings from clinical laboratory tests, such as hematology,
             blood chemistry, urinalysis and immunoserology, and ECG, as conducted by a responsible
             doctor depending on characteristics of the drug

          -  Written consent on voluntary decision of participation and compliance with precautions
             after being fully informed of and completely understanding this trial

          -  Consent to practice medically acceptable contraception during the trial

        Exclusion Criteria:

          -  Hypersensitivity to a drug containing an ingredient of the investigational product
             (EC-18) or similar ingredient (e.g., deer antler) or other drugs (e.g., aspirin,
             antibiotics) or medical history of clinically significant hypersensitivity

          -  Active infection such as chronic or local infection based on screening tests or
             inquiry, verifiable medical records

          -  Serious infection that required hospitalization or use of antibiotics within 30 days
             prior to the first dose of the investigational product, based on an inquiry or
             verifiable medical records

          -  Presence of a clinically significant hepatic, renal, gastrointestinal, respiratory,
             musculoskeletal, endocrine, nervous, blood, cardiovascular, urogenital, psychiatric
             disorder or its prior history

          -  (1) Presenting tuberculosis or prior history of tuberculosis or (2) positive results
             from a QuantiFERON® -TB Gold in Tube Assay conducted due to a contact with a
             tuberculosis patient within the past 3 months or signs and symptoms of suspected
             tuberculosis

          -  Prior history of a gastrointestinal disorder (e.g., Crohn's disease, ulcer) or surgery
             (except for simple appendectomy or hernia surgery) that may affect drug absorption,
             etc.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Soo Park, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Health System, Severance Hospital (Seoul)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EC-18</keyword>
  <keyword>Hematology</keyword>
  <keyword>Cancer</keyword>
  <keyword>Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>I will update the status when it is decided.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>June 10, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>October 16, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>October 17, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

